Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yongnian Sun

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
ACS Medicinal Chemistry Letters|June 25, 2025
New Multiparameter Index Is a Strong Predictor of Oral Bioavailability for Heterobifunctional DegradersJavier L Baylon, Matthew J Chalkley, Tony Siu, et al.
Journal of Virology|August 4, 2019
GSK3732394: a Multi-specific Inhibitor of HIV EntryDavid Wensel, Yongnian Sun, Jonathan Davis, et al.
Antimicrobial Agents and Chemotherapy|August 28, 2013
In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutationsZhufang Li, Brian Terry, William Olds, et al.
ACS Medicinal Chemistry Letters|July 21, 2015
Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse TranscriptaseBryan D Cox, Anthony R Prosser, Yongnian Sun, et al.
Virology|April 20, 2010
Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodiesNannan Zhou, Li Fan, Hsu-Tso Ho, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|June 1, 2023
Mechanistic investigation of liver injury induced by BMS-932481, an experimental ɣ-secretase modulatorXiaoliang Zhuo, Brett A Howell, Hong Shen, et al.
Biopharmaceutics & Drug Disposition|December 23, 2020
Pharmacodynamics-based approach for efficacious human dose projection of BMS-986260, a small molecule transforming growth factor beta receptor 1 inhibitorKaren E Parrish, Jesse Swanson, Lihong Cheng, et al.
Antimicrobial Agents and Chemotherapy|April 20, 2016
Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic CoverageBeata Nowicka-Sans, Tricia Protack, Zeyu Lin, et al.
Journal of Medicinal Chemistry|January 31, 2013
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-585248)Alicia Regueiro-Ren, Qiufen M Xue, Jacob J Swidorski, et al.
Journal of Medicinal Chemistry|February 17, 2026
From Lead to Clinical Candidate: Discovery of BMS-986331 as a Potent and Selective <i>N</i>-Formyl Peptide Receptor 2 AgonistPravin S Shirude, Daniel Cheney, Amit K Chattopadhyay, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
ACS Medicinal Chemistry Letters|June 25, 2025
New Multiparameter Index Is a Strong Predictor of Oral Bioavailability for Heterobifunctional DegradersJavier L Baylon, Matthew J Chalkley, Tony Siu, et al.
Journal of Virology|August 4, 2019
GSK3732394: a Multi-specific Inhibitor of HIV EntryDavid Wensel, Yongnian Sun, Jonathan Davis, et al.
Antimicrobial Agents and Chemotherapy|August 28, 2013
In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutationsZhufang Li, Brian Terry, William Olds, et al.
ACS Medicinal Chemistry Letters|July 21, 2015
Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse TranscriptaseBryan D Cox, Anthony R Prosser, Yongnian Sun, et al.
Virology|April 20, 2010
Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodiesNannan Zhou, Li Fan, Hsu-Tso Ho, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|June 1, 2023
Mechanistic investigation of liver injury induced by BMS-932481, an experimental ɣ-secretase modulatorXiaoliang Zhuo, Brett A Howell, Hong Shen, et al.
Biopharmaceutics & Drug Disposition|December 23, 2020
Pharmacodynamics-based approach for efficacious human dose projection of BMS-986260, a small molecule transforming growth factor beta receptor 1 inhibitorKaren E Parrish, Jesse Swanson, Lihong Cheng, et al.
Antimicrobial Agents and Chemotherapy|April 20, 2016
Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic CoverageBeata Nowicka-Sans, Tricia Protack, Zeyu Lin, et al.
Journal of Medicinal Chemistry|January 31, 2013
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-585248)Alicia Regueiro-Ren, Qiufen M Xue, Jacob J Swidorski, et al.
Journal of Medicinal Chemistry|February 17, 2026
From Lead to Clinical Candidate: Discovery of BMS-986331 as a Potent and Selective <i>N</i>-Formyl Peptide Receptor 2 AgonistPravin S Shirude, Daniel Cheney, Amit K Chattopadhyay, et al.
Pageof 2